Nomenclature	CXCR1	CXCR2	CXCR3	CXCR4	CXCR5	CXCR6	CX 3CR1
HGNC, UniProt	CXCR1, P25024	CXCR2, P25025	CXCR3, P49682	CXCR4, P61073	CXCR5, P32302	CXCR6, O00574	CX3CR1, P49238
Endogenous agonists	CXCL8 (CXCL8, P10145) [145, 711, 1133, 2121, 2137], CXCL6 (CXCL6, P80162) [2141]	CXCL1 (CXCL1, P09341) [711, 1133, 2137], CXCL8 (CXCL8, P10145) [145, 711, 1133, 2121, 2137], CXCL7 (PPBP, P02775) [18], CXCL3 (CXCL3, P19876) [18], CXCL2 (CXCL2, P19875) [18], CXCL5 (CXCL5, P42830) [18], CXCL6 (CXCL6, P80162) [2141]	CXCL11 (CXCL11, O14625) [768], CXCL10 (CXCL10, P02778) [768, 2093], CXCL9 (CXCL9, Q07325) [768, 2093]	CXCL12 α (CXCL12, P48061) [782, 1202], CXCL12 β (CXCL12, P48061) [782]	CXCL13 (CXCL13, O43927) [103]	CXCL16 (CXCL16, Q9H2A7) [2116]	CX 3CL1 (CX3CL1, P78423) [608]
Agonists	vCXCL1 [1223], HIV‐1 matrix protein p17 [637]	vCXCL1 [1223], HIV‐1 matrix protein p17 [637]	–	–	–	–	–
Selective agonists	–	–	–	ALX40‐4C (Partial agonist) [2213], X4‐HIV‐1 gp120	–	–	–
Endogenous antagonists	–	–	CCL11 (CCL11, P51671) (pK i 7.2) [2093], CCL7 (CCL7, P80098) (pK i 6.6) [2093]	–	–	–	–
Antagonists	–	–	–	plerixafor (pK i 7) [2213]	–	–	–
Selective antagonists	–	navarixin (pIC50 10.3) [81, 484], danirixin (pIC50 7.9) [1343], SB 225002 (pIC50 7.7) [2103], elubirixin (pIC50 7.7) [81], SX‐517 (pIC50 7.2) [1236]	–	T134 (pIC50 8.4) [1929], X4P‐001 (pIC50 7.9) [1819], HIV‐Tat	–	–	–
Allosteric modulators	reparixin (Negative) (pIC50 9) [145]	reparixin (Negative) (pIC50 6.4) [145]	–	–	–	–	–
Labelled ligands	[125 I]CXCL8 (human) (Agonist) [711, 1658]	[125 I]CXCL8 (human) (Agonist) [711, 1658], [125 I]CXCL1 (human) (Agonist), [125 I]CXCL5 (human) (Agonist), [125 I]CXCL7 (human) (Agonist)	[125 I]CXCL10 (human) (Agonist), [125 I]CXCL11 (human) (Agonist)	[125 I]CXCL12 α (human) (Agonist) [444, 782]	[125 I]CXCL13 (mouse) (Agonist) [227] – Mouse	[125 I]CXCL16 (human) (Agonist)	[125 I]CX 3CL1(human) (Agonist)